drugset / Trial / NCT04670666

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

NCT04670666

Phase 3 Recruiting 270 enrolled EMS
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Madalena association in the treatment of type 2 diabetes mellitus.

Timeline

Start
2024-11-18
Primary completion
2026-07
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule 10 mg Oral
Comparator Linagliptin Small molecule 5 mg Oral
Subject MADALENA ASSOCIATION Unknown Oral
Comparator Metformin Small molecule 1000 mg Oral